stockportfolio.pro
Omnicell, Inc. (OMCL)
Healthcare · Health Information Services · NasdaqGS
Omnicell, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $695.91M | $712.71M | $787.31M | $897.03M | $892.21M | $1.13B | $1.30B | $1.15B | $1.11B | $1.18B |
| Gross profit | $317.08M | $318.64M | $372.33M | $436.91M | $413.29M | $554.65M | $588.99M | $496.84M | $471.00M | $503.44M |
| Net income | $9.76M | $30.52M | $37.73M | $61.34M | $32.19M | $77.85M | $5.65M | $-20.37M | $12.53M | $2.05M |
| Net margin | 1.4% | 4.3% | 4.8% | 6.8% | 3.6% | 6.9% | 0.4% | -1.8% | 1.1% | 0.2% |
Source: Omnicell, Inc. SEC filings (10-K). 17 years of history available in the interactive view.
What growth is priced into OMCL stock?
At today's market cap of $1.75B, Omnicell, Inc. is priced for free-cash-flow growth of about 7.8% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $86.89M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -11.8%/yr over the last five fiscal years and revenue 5.8%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 17 years of Omnicell, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track OMCL in your portfolio →
Omnicell, Inc. financial history by metric
About Omnicell, Inc.
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Omnicell, Inc. — frequently asked questions
What is Omnicell, Inc.'s revenue?
Omnicell, Inc. (OMCL) reported revenue of $1.18B for fiscal year 2025, up 6.5% from the prior year, according to its SEC filings.
Is Omnicell, Inc. profitable?
Yes. OMCL earned net income of $2.05M in fiscal 2025, a net margin of 0.2%.
What is OMCL's P/E ratio?
Omnicell, Inc. trades at a price-to-earnings ratio of about 87.3 based on the latest data in our nightly-refreshed cache.
How fast is Omnicell, Inc. growing?
OMCL's revenue grew at roughly 5.8% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Omnicell, Inc. have?
As of fiscal year 2025, OMCL carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Omnicell, Inc.'s gross margin?
OMCL's gross margin was 42.5% in fiscal 2025 — gross profit of $503.44M on revenue of $1.18B.
What is Omnicell, Inc.'s market cap?
Omnicell, Inc. (OMCL) has a market capitalization of about $1.75B, based on the latest data in our nightly-refreshed cache.
When does Omnicell, Inc.'s fiscal year end?
OMCL's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into OMCL stock?
At today's market cap of $1.75B, Omnicell, Inc. is priced for free-cash-flow growth of about 7.8% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $86.89M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -11.8%/yr over the last five fiscal years and revenue 5.8%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Omnicell, Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.